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Edited by Noboru MizushimaAbstract Jun-dimerization protein 2 (JDP2) is a member of the
activating protein-1 (AP-1) family of transcription factors.
JDP2 dimerizes with other AP-1 proteins such as activating
transcription factor-2 (ATF2) and Jun to repress transcription
from promoters that contain a cyclic AMP-responsive element
(CRE). Interferon regulatory factor-2-binding protein-1 (IRF2-
BP1), which is reported to be a transcriptional corepressor of
IRF2, was isolated as a JDP2-binding protein using an epi-
tope-tagging method. As anticipated from the presence of a
RING-ﬁnger domain, IRF2-BP1 enhanced the polyubiquitina-
tion of JDP2. Moreover, IRF2-BP1 repressed ATF2-mediated
transcriptional activation from a CRE-containing promoter.
Structured summary:
MINT-6699624:
JDP2 (uniprotkb:Q8WYK2) physically interacts (MI:0218)
with Valyl-tRNA synthetase (uniprotkb:P26640), IRF2-BP1
(uniprotkb:Q8IU81), ATF7 (uniprotkb:P17544), EEF1G (uni-
protkb:P26641), EEF1A1 (uniprotkb:P68104), JUND (uni-
protkb:P17535), JUNB (uniprotkb:P17275), EF1D2
(uniprotkb:P29692) and RPLP0 (uniprotkb:P05388) by anti
tag coimmunoprecipitation (MI:0007).
MINT-6699850:
JDP2 (uniprotkb:Q8WYK2) binds (MI:0407) to IRF2-BP1
(uniprotkb:Q8IU81) by pull down (MI:0096).
MINT-6699684:
JDP2 (uniprotkb:Q8WYK2) physically interacts (MI:0218)
with JUNB (uniprotkb:P17275), JUND (uniprotkb:P17535),
ATF7 (uniprotkb:P17544) and IRF2-BP1 (uniprotkb:Q8IU81)
by anti tag coimmunoprecipitation (MI:0007).
MINT-6699839:
IRF2-BP1 (uniprotkb:Q8IU81) physically interacts (MI:0218)
with JDP2 (uniprotkb:Q8WYK2) by anti bait coimmunopre-
cipitation (MI:0006).
MINT-6699748:
JDP2 (uniprotkb:Q8WYK2) physically interacts (MI:0218)
with ATF2 (uniprotkb:P15336) and c-JUN (uniprotkb:P05412)
by anti tag coimmunoprecipitation (MI:0007).
MINT-6699865:Abbreviations: AP-1, activating protein-1; ATF, activating transcrip-
tion factor; CRE, cyclic AMP-responsive element; DTT, dithiothreitol;
HA, hemagglutinin; IRF, interferon regulatory factor; IRF2-BP1,
IRF2-binding protein-1; JDP2, Jun-dimerization protein 2; PMSF,
phenylmethylsulfonyl ﬂuoride
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Transcriptional repression1. Introduction
Activating protein-1 (AP-1) proteins are transcription fac-
tors that are composed of hetero- or homodimers of basic leu-
cine zipper proteins, many of which belong to the Jun, Fos, or
activating transcription factor (ATF) families. These proteins
control cell proliferation and diﬀerentiation by regulating the
expression of cell cycle-related genes and function in both
pro- and anti-apoptotic processes [1]. In addition, AP-1 pro-
teins play roles in the induction of interferon-b; the incorpora-
tion of the ATF2/c-Jun heterodimer into a complex with
interferon regulatory factors (IRFs) is essential for the tran-
scriptional activation [2].
Jun-dimerization protein (JDP2), another AP-1 protein, is
a dimerization partner of Jun [3] and ATF2 [4] and represses
transcriptional activation. JDP2 has eﬀects on various cellu-
lar processes. It mediates the diﬀerentiation of myoblasts [5]
and osteoclasts [6], inhibits the diﬀerentiation of adipocytes
[7] and embryonic carcinoma cells [8], acts as a tumor sup-
pressor in NIH3T3 cells and prostate cancer cell lines [9], in-
duces the partial transformation of chick embryonic
ﬁbroblasts [10], and functions as a cell-survival protein [11]
and as a progesterone receptor coactivator [12]. The mecha-
nisms of JDP2-mediated transcriptional repression may in-
clude the regulation of nucleosome assembly and histone
acetylation [13]. These diverse functions of JDP2 suggest
that it cooperates with various proteins to mediate
regulatory activity.2. Materials and methods
2.1. Plasmids
Human IRF2-BP1 cDNA was obtained from the American Type
Culture Collection (ATCC number 9115061); JDP2 and ATF2 cDNA
was isolated from HeLa cells using PCR. The plasmids pIRES-JDP2
and pIRES-f-JDP2 contain untagged and N-terminally FLAG-
tagged JDP2 cDNA, respectively, within pIRESneo3 (Clon-
tech). The pcDNA-IRF2BP1, pcDNA-ATF2, pcDNA-JDP2, andblished by Elsevier B.V. All rights reserved.
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(Invitrogen). The pcDNA-IRF2BP1DR and pcDNA-IRF2BP1sub
contain either a termination codon after position 501 or Cys527Ser
and Cys530Ser mutations, respectively, within the IRF2-BP1 open
reading frame. The phRL-3CRE-TK (RIKEN DNA bank number
3459) is a derivative of phRL-TK (Promega) that has three cyclic
AMP-responsive elements (CREs) inserted upstream of the promoter.
The pMT123 encodes a hemagglutinin (HA)-tagged precursor of ubiq-
uitin [14].
2.2. Cells
HeLa-S3, HeLa-G, and HepG2 cells were obtained from the RI-
KEN Cell Bank. To establish the stable transformant lines HeLa/
JDP2 and HeLa/f-JDP2, HeLa-S3 cells were transfected with pIRES-
JDP2 and pIRES-f-JDP2, respectively, and cloned.2.3. Antibodies
Antibodies against IRF2-binding protein-1 (IRF2-BP1) and JDP2
were raised in rabbits immunized with bacterially expressed His6-
tagged IRF2-BP1 and JDP2 proteins, respectively. Other polyclonal
antibodies were obtained from Santa Cruz Biotechnology. FLAG-spe-
ciﬁc (M2) and HA-speciﬁc (12CA5) monoclonal antibodies were ob-
tained from Sigma and Roche, respectively.2.4. Isolation and identiﬁcation of JDP2-binding proteins
Nuclear extracts were prepared from HeLa/JDP2 and HeLa/f-JDP2
cells as described [15]. After the extracts were prepared in BC buﬀer
[20 mM Tris–HCl (pH 8.0 at 4 C), 20% glycerol, 0.2 mM EDTA,
0.5 mM phenylmethylsulfonyl ﬂuoride (PMSF), 1 mM dithiothreitol
(DTT)] containing 100 mM KCl and 0.5% Nonidet P-40, the FLAG-
tagged protein complexes were collected with M2 antibody-conjugated
agarose (Sigma) in a batch procedure over 4 h at 4 C. The M2-agarose
was then washed four times with BC buﬀer containing 300 mM KCl
and 0.5% Nonidet P-40, and the proteins were eluted with BC buﬀer
containing 100 mM NaCl, 0.1% Nonidet P-40, and 200 lg/ml
FLAG-peptide (Sigma). Following SDS–PAGE, JDP2-binding pro-
teins were subjected to in-gel trypsin digestion. The molecular masses
of the eluted peptides were determined using a matrix-assisted laser
desorption/ionization time-of-ﬂight mass spectrometer (Shimadzu)
and searched against a database using the MS-Fit program (University
of California, San Francisco).2.5. Immunoprecipitation
A nuclear extract of HeLa/f-JDP2 cells was prepared in nuclear buf-
fer [420 mM NaCl, 20 mM Tris–HCl (pH 8.0 at 4 C), 1.5 mMMgCl2,
0.2 mM EDTA, 25% glycerol, 0.5 mM PMSF, 2 mM DTT] [15] and
precleared with protein A-Sepharose (GE Healthcare). Antibodies
conjugated to protein A-Sepharose were added to the precleared nucle-
ar extract, and the mixture was rocked for 4 h at 4 C. After four
washes with BC buﬀer containing 400 mM KCl and 0.5% Nonidet
P-40, proteins bound to the protein A-Sepharose were eluted with
SDS–PAGE sample buﬀer.2.6. Glutathione S-transferase (GST) pull-down assay
The GST fusion proteins GST-JDP2, GST-ATF2, and GST were ex-
pressed in Escherichia coli and puriﬁed using glutathione-Sepharose
(GE Healthcare). The 35S-labeled IRF2-BP1 was prepared by
in vitro transcription and translation using the TNT-Coupled Reticu-
locyte Lysate System (Promega). The GST fusion proteins were bound
to glutathione-Sepharose and then mixed with the in vitro-translation
products in binding buﬀer [200 mMNaCl, 20 mM Tris–HCl (pH 8.0 at
4 C), 20% glycerol, 1 mM EDTA, 0.5 mM PMSF, 0.5% Nonidet P-
40]. After rocking for 2 h at 4 C and four washes, the proteins bound
to glutathione-sepharose were eluted with SDS–PAGE sample buﬀer.
The radioactivity in the SDS–PAGE gel was visualized using a
BAS2500 image analyzer (Fuji).2.7. Ubiquitination assay
HeLa-G cells in 10-cm dishes were co-transfected with plasmids
(Fig. 3). The pMT123, pcDNA-JDP2-His, pcDNA-IRF2BP1,
pcDNA-IRF2BP1DR, pcDNA-IRF2BP1sub, and pcDNA3 (8 lg each)were used for transfection. After a 24-h incubation, MG132 (Peptide
Institute) was added to a ﬁnal concentration of 5 lM, and the cells were
incubated for another 4 h. The cells were washed and lysed in denatur-
ation buﬀer [6 M guanidine–HCl, 100 mM Tris–HCl (pH 8.0 at 4 C),
5 mM imidazole]. The His6-tagged JDP2 was puriﬁed from the
denatured cell lysate using Ni2+-nitrilotriacetic acid agarose (Qiagen)
as described [14] and analyzed by Western blotting with antibodies
speciﬁc to the HA-tag or JDP2. Signals were visualized by chemilumi-
nescence and quantiﬁed with a LuminoImage analyzer Las-3000 (Fuji).
2.8. Luciferase assay
HepG2 cells were seeded in a 96-well plate at 6 · 104 cells/well and
incubated for 24 h. The cells were then co-transfected with plasmid
(Fig. 4). After incubating for 29 h, luminescence was measured using
the Renilla Luciferase Assay System (Promega) and an ARVO Light
Luminescence Counter (Perkin–Elmer). The results are provided as
the mean ± S.E. (n = 4) relative to the value for the reporter alone,
which was deﬁned as 1.0.3. Results
3.1. IRF2-BP1 associates with JDP2
FLAG-JDP2 and associated proteins were isolated from nu-
clear extracts of the stably transformed cell lines HeLa/JDP2
and HeLa/f-JDP2, which express untagged and FLAG-tagged
JDP2, respectively, using the FLAG-speciﬁc M2 antibody. The
proteins that were recovered from HeLa/f-JDP2, but not from
HeLa/JDP2, were identiﬁed using peptide mass ﬁngerprinting
(Fig. 1A and Supplementary Fig. S1). The identiﬁcation of
transcription-related proteins was conﬁrmed by Western blot-
ting (Fig. 1B). Interactions between JDP2 and ATF7 or IRF2-
BP1 have not been reported previously.
Translation factors were also among the isolated proteins
(Fig. 1A and Supplementary Fig. S1). The isolation of JunB
and JunD, which are conﬁrmed partners of JDP2, supports
the hypothesis that these proteins are associated with JDP2.
The formation of a complex of valyl-tRNA synthetase and
EF-1 proteins has been reported [16].
Because we did not ﬁnd certain proteins that were previously
reported to interact with JDP2, their possible presence in the
isolated JDP2 complexes was examined by Western blotting
(Fig. 1C). Both c-Jun and ATF2 were detected in the com-
plexes, but neither histone deacetylase-3 nor p300 was de-
tected.
The interaction between IRF2-BP1 and JDP2 was con-
ﬁrmed. FLAG-JDP2 was precipitated from the HeLa/f-
JDP2 nuclear extract using IRF2-BP1-speciﬁc antiserum,
but not preimmune serum (Fig. 2A). In addition, in vitro-
translated IRF2-BP1 was bound to GST-JDP2, but not to
GST (Fig. 2B).
3.2. IRF2-BP1 enhances the ubiquitination of JDP2
A region in the C-terminal portion of IRF2-BP1 is approx-
imately 90% homologous to the RING-ﬁnger domain of
KIAA1865 (Fig. 3A), for which the three-dimensional struc-
ture has been solved by NMR (Protein Data Bank number
2cs3). Thus, this region in IRF2-BP1 is reasonably assumed
to be a RING-ﬁnger domain.
Because many RING-ﬁnger proteins show ubiquitin ligase
E3 activity [17], the possible ubiquitination of JDP2 by
IRF2-BP1 was examined. His6-tagged JDP2, HA-tagged ubiq-
uitin precursor, and IRF2-BP1 were expressed in cultured
cells, and the ubiquitination of the puriﬁed JDP2-His was
Fig. 1. (A) JDP2-binding proteins were isolated from nuclear extracts of HeLa/JDP2 (JDP2) and HeLa/f-JDP2 (FLAG-JDP2) cells using FLAG-
speciﬁc M2 antibody and electrophoresed on 7.5% and 12.5% polyacrylamide gels. The proteins identiﬁed by peptide mass ﬁngerprinting are denoted
with accession numbers. EF-1a1 was present in the pair of bands. Both JunB and JunD were identiﬁed in band F. (B) Nuclear extracts (N.E.) and
M2-aﬃnity-puriﬁed fractions from each cell line were subjected to Western blotting with speciﬁc antibodies. Certain proteins were concentrated in
the M2-aﬃnity-puriﬁed fractions. FLAG-JDP2 migrated more slowly than untagged JDP2 during SDS–PAGE. No endogenous JDP2 was detected.
The asterisk denotes the light chain of the M2 antibody. (C) The same fractions were subjected to Western blotting with antibodies speciﬁc to
proteins that were expected to interact with JDP2 but were not identiﬁed in (A).
Fig. 2. (A) Fractions immunoprecipitated (I.P.) from a HeLa/f-JDP2 nuclear extract with IRF2-BP1-speciﬁc or preimmune antibody were probed
with anti-IRF2-BP1 and anti-JDP2 antibodies by Western blotting (W.B.). (B and C) (Left) Coomassie Brilliant Blue (CBB) staining of the used
proteins. (Right) 35S-labeled IRF2-BP1 translated in vitro was used in a GST pull-down assay. The input and bound (Pull down) fractions were
subjected to SDS–PAGE and images of the gels were collected by an imaging plate.
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immunoreactive to the HA-speciﬁc antibody (Fig. 3B, upperpanel) could be attributed to poly-HA-ubiquitinated JDP2-
His because cells expressing either JDP2-His or HA-ubiquitin
Fig. 3. (A) Sequence alignment of the RING-ﬁnger domains of IRF2-
BP1 (AAP78943) and KIAA1865 (BAB47494). Identical residues are
shaded and amino acid positions are indicated. Triangles indicate Cys
residues substituted by Ser residues in the IRF2-BP1sub mutant. (B)
HeLa-G cells were co-transfected with expression plasmids for JDP2-
His, HA-ubiquitin precursor, or IRF2-BP1 in the indicated combina-
tions. Lanes 9 and 10 contain plasmids expressing IRF2-BP1DR and
IRF2-BP1sub, respectively, in place of the wild-type IRF2-BP1. The
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Fig. 4. Luciferase assay. The phRL-3CRE-TK reporter plasmid
(50 ng/well), pcDNA-ATF2 (50 ng/well), and varying amounts of
pcDNA-JDP2, pcDNA-IRF2BP1, and pcDNA3 (Vector) were co-
transfected. Incremental shading indicates 6.3, 25, and 100 ng/well of
2836 M. Kimura / FEBS Letters 582 (2008) 2833–2837alone did not show these bands (lanes 2–6). When IRF2-BP1
was co-expressed with both JDP2-His and HA-ubiquitin, the
level of JDP2-His did not change (lanes 7 and 8, lower panel),
but the intensity of the polyubiquitination was enhanced
1.84 ± 0.48-fold (upper panel) in three independent experi-
ments. The expression of IRF2-BP1 DR (lane 9), which lacks
the RING-ﬁnger domain, and of IRF2-BP1sub (lane 10),
which has two Cys-to-Ser substitutions within its RING-ﬁnger
domain (Fig. 3A), did not increase the ubiquitination of JDP2.
the plasmids. The amounts of DNA were equalized by the addition of
pUC19. (A) JDP2 represses ATF2-dependent activation. (B) IRF2-
BP1 represses ATF2-dependent activation in the presence and absence
of JDP2. The amounts of pcDNA-JDP2 (6.3 ng/well) in columns 9–15
were balanced in columns 1–8 by the vector (shaded horizontal bar).
(C) The ubiquitin ligase activity of IRF2-BP1 is not essential for
transcriptional repression. IRF2BP1DR or IRF2BP1sub, both lacking
ubiquitin ligase activity, were expressed.3.3. IRF2-BP1 represses ATF2-dependent transcriptional
activation
The eﬀects of IRF2-BP1 on ATF2- and JDP2-mediated
transcriptional regulation were examined using a luciferase as-
say system. ATF2-dependent activation of a CRE-containing
promoter and dose-dependent inhibition of it by JDP2 were
observed (Fig. 4A). IRF2-BP1 repressed ATF2-dependent
activation in a dose-dependent manner in the absence of plas-
mid-encoded JDP2 (Fig. 4B, columns 2–5). When JDP2 was
expressed at a level that partially inhibited ATF2-dependent
activation (column 9), IRF2-BP1 still repressed transcription
(columns 10–12), and the relative extents of repression were
similar to those in the absence of JDP2 (columns 3–5). There-
fore, the eﬀects of IRF2BP1 and JDP2 on the ATF2-depen-
dent activation are additive.
The repression by IRF2-BP1 observed in the absence of
plasmid-encoded JDP2 raised the possibility that IRF2-BP1
might interact directly with ATF2. IRF2-BP1 was pulled down
by GST-ATF2, but not by GST (Fig. 2C), indicating that
ATF2 and IRF2-BP1 can interact directly. No IRF2-BP1-dependent ubiquitination of ATF2 was observed (data not
shown).
The relationship between the ubiquitin ligase and transcrip-
tional inhibitor activities of IRF2-BP1 was addressed. Activa-
tion was repressed when either IRF2-BP1DR or IRF2-BP1sub,
which both lack ligase activity (Fig. 3B), was co-expressed with
ATF2 (Fig. 4C, columns 6–11). Thus, the repression occurred
independently of ubiquitin ligase activity.4. Discussion
IRF2-BP1 was originally reported to be a corepressor for
IRF2 [18], which is a repressor of the interferon-b gene.
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the same regulatory elements [19]. Importantly, the ATF2/c-
Jun heterodimer binds to a site adjacent to the IRF-binding
elements during the induction of interferon-b [2]. Because
JDP2 represses activation by ATF2 and c-Jun, IRF2-BP1
might interact with both IRF2 and JDP2 as a corepressor.
Polyubiquitination of a protein is generally a prelude to deg-
radation. The two functions of IRF2-BP1, i.e., repression and
ubiquitination, might therefore be in conﬂict. However, ubiq-
uitin ligase activity is not required for transcriptional repres-
sion. Hence, it is possible that in the repressor complex,
IRF2-BP1 does not ubiquitinate JDP2, whereas under some
circumstances, it is activated to ubiquitinate JDP2, leading to
JDP2 degradation and transcriptional activation. To support
this hypothesis, the participation of a ubiquitin-speciﬁc prote-
ase like HAUSP for p53 [20] and USP28 for Myc [21] can be
postulated.
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